Streetbeat News

Products Services

VRTX

Vertex Pharmaceuticals provided its FY24 financial guidance, projecting product revenues of $10.55B-$10.75B, driven by growth in CF treatments and the launch of CASGEVY. Expenses are expected to be $4.3B-$4.4B. Key highlights include the expansion of CF patient base and approvals for KAFTRIO in the EU and UK for younger patients, and a pending approval for additional CF mutations in the EU and other regions.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 9:08 pm

RARE

Ultragenyx Pharmaceutical Inc. has received PRIME designation from the European Medicines Agency (EMA) for GTX-102, a therapeutic candidate for Angelman Syndrome. This marks the first time a treatment for Angelman Syndrome has received such designation. The Phase 1/2 study for GTX-102 is fully enrolled, with expansion data anticipated in the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 9:06 pm

XCUR

Exicure and Bluejay Therapeutics have entered into a patent license agreement for the development of Cavrotolimod for hepatitis. Bluejay receives an exclusive license to Exicure's patents in this field, with an initial payment made to Exicure and future royalties on net sales agreed upon. Exicure retains responsibility for the patents' maintenance and legal processes.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 9:03 pm

VRTX

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced positive results from its Phase 3 trials of the vanzacaftor/tezacaftor/deutivacaftor regimen for cystic fibrosis, showing non-inferiority to TRIKAFTA in improving lung function and superiority in reducing sweat chloride levels. The regimen was well tolerated, and Vertex plans to file for global approval for ages 6 and older by mid-2024.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 9:02 pm

PRIM

Primoris Services Corporation (NYSE:PRIM) announced awards totaling approximately $1.1 billion for its Energy Segment, including over $700 million for utility-scale solar projects and more than $350 million for a natural gas repowering project with battery energy storage. These projects, spanning three states, are set to begin between the second quarter of 2024 and early 2025, marking significant growth in the company's project backlog.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 9:01 pm

BTCUSD

Chris Burniske, former ARK Invest Crypto Lead, shared five critical tips for cryptocurrency investors on X, emphasizing the importance of personal responsibility, developing one's own investing practice, staying open-minded, having a clear strategy, and understanding sources thoroughly. He highlighted the risks of blindly following others and the necessity of a well-defined investment approach to avoid potential losses.

Portfolio Pulse from Ivan Crnogatić

February 05, 2024 | 8:27 pm

BHP

IVPAF

RTNTF

ZIJMF

KoBold Metals, supported by billionaires including Bill Gates and Jeff Bezos, announced a historic copper discovery in Zambia, potentially the largest in the country's history. The Mingomba asset could rival the Kamoa-Kakula mine, operated by Ivanhoe Mines Ltd (OTC:IVPAF) and Zijin Mining Group (OTC:ZIJMF), which produced almost 400,000 tons of copper in 2023. KoBold plans to fast-track the development of this $2 billion mine for production in the early 2030s. The company spent $100 million on exploration in 2023, with plans to exceed this in 2024, aligning with the spending of giants like BHP Group (NYSE:BHP) and Rio Tinto Ltd. (OTC:RTNTF).

Portfolio Pulse from Stjepan Kalinic

February 05, 2024 | 8:22 pm

IMMX

Immix Biopharma, Inc. (NASDAQ:IMMX), a clinical-stage biopharmaceutical company, announced its intention to offer and sell shares of its common stock in an underwritten public offering. The offering's size and terms are yet to be disclosed and are subject to market conditions. The company plans to use the net proceeds for NXC-201 clinical trials, working capital, and general corporate purposes. Titan Partners Group, LLC is the sole book-running manager for the offering.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 8:21 pm

LLY

Eli Lilly has announced that it anticipates intermittent backorders of the 10mg, 12.5mg, and 15mg doses of Mounjaro through early March 2024, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

February 05, 2024 | 8:16 pm

CAT

Caterpillar Inc (NYSE:CAT) shares reached new all-time highs following strong quarterly results, with a 3% revenue increase in Q4 and 13% for 2023. CEO Jim Umpleby highlighted expanding market opportunities in cloud computing and generative AI, driving demand for data center power generation. The company is making significant investments in manufacturing capacity for large engines to meet this demand and capitalize on long-term growth opportunities.

Portfolio Pulse from Adam Eckert

February 05, 2024 | 8:09 pm